Intrinsiqq
Belite Bio, Inc. ADR logo

Belite Bio, Inc. ADR Insider Trading

BLTE

Compare
Last 12 months

Insiders sold $41M and bought nothing on the open market.

93% of the selling was scheduled in advance under 10b5-1 plans. Chief Medical Officer Hendrik Peter Scholl sold $1.45M on Jun 18, 40% of their stake, outside a plan. No executive or director has bought shares on the open market in the last two years.

Net open-market
−$41M
0 buys · 28 sales
Under a 10b5-1 plan
93%
of the value sold
Insiders who bought / sold
0 / 5
executives and directors
Last open-market buy
None
in the last two years

Get an email when BLTE's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Nov 1210b5-1 plan
    Hendrik Peter Scholl
    Chief Medical Officer · sold 2,000 at avg $165.99
    332K
    14% of stake
  • Oct 110b5-1 plan
    Hendrik Peter Scholl
    Chief Medical Officer · sold 500 at avg $165.32
    83K
    3.3% of stake
  • Sep 4 – 810b5-1 plan
    Yu-Hsin Lin
    Chief Executive Officer · sold 100,435 at avg $190.00
    $19.1M
    59% of stake
  • Sep 4 – 810b5-1 plan
    Hao-Yuan Chuang
    Chief Financial Officer · sold 67,395 at avg $189.98
    $12.8M
    72% of stake
  • Aug 1210b5-1 plan
    Hao-Yuan Chuang
    Chief Financial Officer · sold 367 at avg $180.35
    66K
    0.4% of stake
  • Aug 1210b5-1 plan
    Yu-Hsin Lin
    Chief Executive Officer · sold 365 at avg $180.35
    66K
    0.2% of stake
  • Jun 18No plan
    Hendrik Peter Scholl
    Chief Medical Officer · sold 10,000 at avg $145.24
    $1.45M
    40% of stake
  • Jun 16No plan
    Hendrik Peter Scholl
    Chief Medical Officer · sold 10,000 at avg $140.57
    $1.41M
    29% of stake
  • May 710b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 666 at avg $153.21
    102K
    100% of stake
  • May 610b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $153.84
    154K
    60% of stake
  • May 510b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $155.50
    156K
    38% of stake
  • May 410b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $155.64
    156K
    27% of stake
  • May 110b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $155.78
    156K
    21% of stake
  • Apr 3010b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $156.97
    157K
    18% of stake
  • Apr 2910b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $155.82
    156K
    15% of stake
  • Apr 2810b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $159.16
    159K
    13% of stake
  • Apr 2710b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $162.64
    163K
    12% of stake
  • Apr 2410b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $159.56
    160K
    10% of stake
  • Apr 2310b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $166.28
    166K
    9.4% of stake
  • Apr 2210b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $170.39
    170K
    8.6% of stake
  • Apr 2110b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $166.00
    166K
    7.9% of stake
  • Apr 2010b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $163.60
    164K
    7.3% of stake
  • Apr 1710b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $161.63
    162K
    6.8% of stake
  • Apr 1610b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $160.38
    160K
    6.4% of stake
  • Apr 1510b5-1 plan
    Nathan L. Mata
    Chief Scientific Officer · sold 1,000 at avg $168.30
    168K
    6.0% of stake
  • Apr 910b5-1 plan
    Yu-Hsin Lin
    Chief Executive Officer · sold 9,200 at avg $181.45
    $1.67M
    5.1% of stake
  • Apr 910b5-1 plan
    Wan-Shan Chen
    Director · sold 1,100 at $180.43
    198K
    11% of stake
  • Apr 910b5-1 plan
    Hao-Yuan Chuang
    Chief Financial Officer · sold 6,200 at avg $181.50
    $1.13M
    6.2% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch BLTE, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biotechnology · Pick stocks to compare with BLTE

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
HPHA.XETRHeidelberg Pharma AG
€2.01-2.90%10
MEDCL.XPARMedincell SA
€26.70-2.05%40
ZTEKZentek Ltd.
€0.33-0.60%40
XTXXFAdastra Holdings Ltd.
€0.08+0.00%40
XRTXXORTX Therapeutics Inc.
$0.84-5.73%10
VALNValneva SE Sponsored ADR
$5.16-3.82%0
TRIBTrinity Biotech plc Sponsored ADR
$6.24+13.66%10

Held by ETFs

BLTE is in 7 US ETFs. The largest of them, with BLTE's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing BLTE

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.